Acylcarnitines: reflecting or inflicting insulin resistance?

MG Schooneman, FM Vaz, SM Houten, MR Soeters - Diabetes, 2013 - Am Diabetes Assoc
MG Schooneman, FM Vaz, SM Houten, MR Soeters
Diabetes, 2013Am Diabetes Assoc
The incidence of obesity and insulin resistance is growing, and the increase in type 2
diabetes mel-litus (DM2) constitutes one of the biggest challenges for our healthcare
systems. Many theories are proposed for the induction of insulin resistance in glucose and
lipid metabolism and its metabolic sequelae. One of these mechanisms is lipotoxicity (1–4):
excess lipid supply and subsequent lipid accumulation in insulin-sensitive tissues such as
skeletal muscle interfere with insulinresponsive metabolic pathways. Various lipid …
The incidence of obesity and insulin resistance is growing, and the increase in type 2 diabetes mel-litus (DM2) constitutes one of the biggest challenges for our healthcare systems. Many theories are proposed for the induction of insulin resistance in glucose and lipid metabolism and its metabolic sequelae. One of these mechanisms is lipotoxicity (1–4): excess lipid supply and subsequent lipid accumulation in insulin-sensitive tissues such as skeletal muscle interfere with insulinresponsive metabolic pathways. Various lipid intermediates, like ceramides, gangliosides, diacylglycerol, and other metabolites, have been held responsible for insulin resistance (2, 3, 5–10). These intermediates can exert such effects because they are signaling molecules and building blocks of cellular membranes, which harbor the insulin receptor. In addition, lipids play an important role in energy homeostasis. Fatty acids (FA) can be metabolized via mitochondrial FA oxidation (FAO), which yields energy (11). As such, FAO competes with glucose oxidation in a process known as the glucose-FA, or Randle, cycle (12). Muoio and colleagues (1, 13, 14) proposed an alternative mechanism in which FAO rate outpaces the tricarboxylic acid cycle (TCA), thereby leading to the accumulation of intermediary metabolites such as acylcarnitines that may interfere with insulin sensitivity. This accumulation of acylcarnitines corroborates with some human studies showing that acylcarnitines are associated with insulin resistance (15–17). In addition, acylcarnitines have a long history in the diagnosis and neonatal screening of FAO defects and other inborn errors of metabolism (18). This knowledge may aid to understand the interaction between FAO and insulin resistance and fuel future research. In this review, we discuss the role of acylcarnitines in FAO and insulin resistance as emerging from animal and human studies.
Am Diabetes Assoc